Technology
Clinical Leader Solutions Expo: eCOA/ePRO
The next level of clinical trial data capture is here. Gone are the days of paper, illegible handwriting, and data quality nightmares. eCOA, or electronic Clinical Outcome Assessments, and ePRO, or electronic Patient-Reported Outcomes, are revolutionizing the way clinical trials generate data. Both leverage digital tools to collect information electronically, offering a treasure trove of benefits. eCOA acts as the umbrella term, encompassing data from various sources like patients (ePRO), clinicians, observers, and even performance-based assessments. This holistic approach paints a more complete picture of a patient's experience. ePRO, as a subset, shines the spotlight directly on the patient's voice, capturing their symptoms, quality of life, and other critical self-reported measures.
Hear from industry leaders at this unique virtual event showcasing the eCOA/ePRO solutions of partners who are ready to help you with your clinical trial data capture needs. Early registration is open via the form to your right.
Amplifying Evidence with Unified Clinical Trial Data Collection
Join us for a discussion about how combining a unified clinical trial data collection platform with intelligent automation can revolutionize drug development and why the current status quo is no longer sufficient. With novel capabilities, the industry can now explore new possibilities, such as incorporating additional sensors to identify surrogate or alternative endpoints, rethinking adaptive trial designs, and quickly responding to emerging data.
Digital vs digitized: Common myths about eConsent for clinical trials
Alex Burrington, CTI Principal of Vertex, and Andrew Mckinnon, VP, GM of eConsent discuss common myths around eConsent, how to improve comprehension with patient-centric consent, and how to use a digital consent management tool to improve trial compliance, quality, and oversight.
Clinician Reported Outcomes (CROs): A universal approach
Get the basics on ClinROs, why they are important, the industry governance around them, and how their electronic versions can benefit clinical trials.